Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Gastric04: Trastuzumab Deruxtecan in HER2-Positive Gastric or GEJ Adenocarcinoma
NCT04704934Phase 3Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2021
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 24
01
Overview
Phase 3, randomised, open-label trial of trastuzumab deruxtecan in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Overall Survival at 36 months. Started May 2021; status: active, not recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04704934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04704934.